167 related articles for article (PubMed ID: 9144878)
1. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy--a phase I/II study.
de Reijke TM; de Boer EC; Schamhart DH; Kurth KH
Urol Res; 1997; 25(2):117-20. PubMed ID: 9144878
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study.
de Boer EC; De Reijke TM; Vos PC; Kurth KH; Schamhart DH
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S109-14. PubMed ID: 11010835
[TBL] [Abstract][Full Text] [Related]
3. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
4. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.
De Boer EC; De Jong WH; Steerenberg PA; Van der Meijden AP; Aarden LA; Debruyne FM; Ruitenberg EJ
In Vivo; 1991; 5(6):671-7. PubMed ID: 1810454
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
6. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.
Böhle A; Nowc C; Ulmer AJ; Musehold J; Gerdes J; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):59-64. PubMed ID: 2193171
[TBL] [Abstract][Full Text] [Related]
7. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
[TBL] [Abstract][Full Text] [Related]
8. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
[TBL] [Abstract][Full Text] [Related]
9. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
10. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
11. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
[TBL] [Abstract][Full Text] [Related]
12. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
13. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
[TBL] [Abstract][Full Text] [Related]
14. Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
de Boer EC; De Reijke TM; Schamhart DH; Vos PC; Kurth KH
Urol Res; 1993; 21(6):423-7. PubMed ID: 8171765
[TBL] [Abstract][Full Text] [Related]
15. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.
Elsässer-Beile U; Gutzeit O; Bauer S; Katzenwadel A; Schultze-Seemann W; Wetterauer U
J Urol; 2000 Jan; 163(1):296-9. PubMed ID: 10604379
[TBL] [Abstract][Full Text] [Related]
16. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).
de Reijke TM; Vos PC; de Boer EC; Bevers RF; de Muinck Keizer WH; Kurth KH; Schamhart DH
Urol Res; 1993; 21(5):349-52. PubMed ID: 8279092
[TBL] [Abstract][Full Text] [Related]
17. Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.
Stassar MJ; Vegt PD; Steerenberg PA; van der Meijden AP; Meiring HD; Dessens-Kroon M; Geertzen HG; den Otter W
Urol Res; 1994; 22(3):177-84. PubMed ID: 7992464
[TBL] [Abstract][Full Text] [Related]
18. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.
de Boer EC; de Jong WH; van der Meijden AP; Steerenberg PA; Witjes F; Vegt PD; Debruyne FM; Ruitenberg EJ
Urol Res; 1991; 19(1):45-50. PubMed ID: 2028562
[TBL] [Abstract][Full Text] [Related]
19. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?
de Reijke TM; De Boer EC; Kurth KH; Schamhart DH
J Urol; 1999 Jan; 161(1):67-71. PubMed ID: 10037371
[TBL] [Abstract][Full Text] [Related]
20. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
